Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Kentucky: - Baptist Health Hardin — Elizabethtown, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Kentucky: - CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- CommonSpirit Saint Joseph Hospital - Lexington — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Kentucky: - CommonSpirit Saint Joseph Hospital - Lexington — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
- Jewish Hospital — Louisville, Kentucky
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Kentucky: - Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Kentucky: - University of Kentucky Chandler Medical Center ( Site 0048) — Lexington, Kentucky
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Kentucky: - University of Kentucky Chandler Medical Center ( Site 0048) — Lexington, Kentucky
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Kentucky: - CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- CommonSpirit Saint Joseph Medical Center - East Lexington — Lexington, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Kentucky: - Flaget Memorial Hospital — Bardstown, Kentucky
- Commonwealth Cancer Center-Corbin — Corbin, Kentucky
- Saint Joseph Hospital — Lexington, Kentucky
- Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
- Saint Joseph Hospital East — Lexington, Kentucky
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Kentucky: - Robley Rex VA Medical Center, Louisville, KY — Louisville, Kentucky
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Kentucky: - Exelixis Clinical Site #122 — Louisville, Kentucky
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Kentucky: - Norton Cancer Institute - Downtown — Louisville, Kentucky
- Norton Cancer Institute, Norton Healthcare Pavilion — Louisville, Kentucky
- Norton Hospital — Louisville, Kentucky
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in Kentucky: - University of Kentucky Markey Cancer Center — Lexington, Kentucky
NA Recruiting Academic/Other
This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood…
Sponsor: University of Kentucky
NCT ID: NCT07594002
Sites in Kentucky: - University of Kentucky — Lexington, Kentucky